Research programme: personalised orphan disease therapeutics - Perlara
Alternative Names: APOL1 kidney disease therapeutic - Perlara; Batten disease therapeutic - Perlara; Leigh syndrome therapeutic - Perlara; NGLY1 therapeutic - Perlara; NPC1 therapeutic - Perlara; PERL 101Latest Information Update: 28 Jan 2023
Price :
$50 *
At a glance
- Originator Perlstein Lab
- Developer Perlara
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Niemann-Pick disease type C
Highest Development Phases
- No development reported Inborn genetic disorders; Kidney disorders; Leigh disease; Mucopolysaccharidosis III; Neuronal ceroid lipofuscinosis; Niemann-Pick disease type C
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for research development in Kidney-disorders in USA
- 28 Oct 2022 No recent reports of development identified for research development in Mucopolysaccharidosis-III in USA
- 28 Feb 2020 No recent reports of development identified for research development in Inborn genetic disorders in USA